Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis Awarded Nearly $1.35 Million to Investigate the Impact of Pediatric-Onset MS Into Adulthood

The Multiple Sclerosis Society of Canada announced today a nearly $1.35 million investment from Biogen Canada Inc., Hoffmann-La Roche Limited, and Brain Canada Foundation towards a new sub-cohort of the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis that follows pediatric-onset MS participants from the Canadian Pediatric Demyelinating Disease Study as they become adults to understand MS across the age-span.